Immune thrombocytopenia in patients with connective tissue disorders and the antiphospholipid antibody syndrome

Hematology/oncology Clinics of North America
Daniel G Arkfeld, Ilene C Weitz

Abstract

It has been theorized that immune thrombocytopenia (ITP) is a syndrome characterized by various defects in immune regulation, resulting in a common phenotype, decreased blood platelets, and symptoms of mucocutaneous bleeding. Most often, successful treatment of the underlying connective tissue disorder with corticosteroids or other disease-modifying agents can simultaneously improve concurrent thrombocytopenia. The best evidence to date would support the targeting of treatment to the connective tissue disorder, expecting a simultaneous improvement in the platelet count. Due to the frequent relapses associated with many of the connective tissue disorders and the frequent use of immunosuppressant agents, splenectomy should be undertaken only in highly refractory patients. Differentiating the varying immunopathic etiologies that contribute to development of connective tissue disorders may lead to a better understanding of the mechanisms of thrombocytopenia in a subset of these patients. The use of target therapies to treat connective tissue disorders has the potential of reducing the risk of the development of ITP or, conversely, inducing the development of immune thrombocytopenia.

References

Jan 1, 1988·European Journal of Pediatrics·T HaraY Yamaguchi
Feb 1, 1985·British Journal of Haematology·E N HarrisG R Hughes
Jan 1, 1995·Seminars in Thrombosis and Hemostasis·B H ChongC N Chesterman
Apr 1, 1996·British Journal of Haematology·M GalliT Barbui
Feb 15, 1997·Annals of Internal Medicine·R McMillan
Jul 10, 2003·Autoimmunity Reviews·Gisele Zandman-Goddard, Yehuda Shoenfeld
Aug 6, 2003·Annals of Internal Medicine·Francesc VidalCristóbal Richart
Aug 28, 2003·Southern Medical Journal·Sandra F WilliamsKenneth T Calamia
Dec 4, 2004·Current Opinion in Rheumatology·Lisa Christopher-Stine, Paul H Plotz
Mar 11, 2005·Medicine·Manuel Ramos-CasalsUNKNOWN SS-HCV Study Group
Aug 9, 2005·Rheumatic Diseases Clinics of North America·Janet E Pope
Oct 26, 2005·American Journal of Hematology·Martine Szyper Kravitz, Yehuda Shoenfeld
Jun 24, 2006·Clinical and Experimental Immunology·P D ZiakasM Voulgarelis
Sep 21, 2006·Blood·Bill GiannakopoulosSteven A Krilis
Jan 31, 2007·Annals of the Rheumatic Diseases·Silvia S PierangeliPier Luigi Meroni
May 29, 2007·Current Rheumatology Reports·Mariano E Vega-Ostertag, Silvia S Pierangeli
Jun 7, 2007·Postgraduate Medical Journal·L CantariniM Galeazzi
Sep 6, 2007·Pediatric Hematology and Oncology·Takeshi AsanoOsamu Fujino
Oct 27, 2007·Seminars in Hematology·Jakob Passweg, Alan Tyndall
Feb 29, 2008·The New England Journal of Medicine·Anisur Rahman, David A Isenberg
Apr 18, 2008·Blood Reviews·Imad UthmanMunther Khamashta
May 31, 2008·British Journal of Haematology·Carole Pierrot-Deseilligny DespujolBertrand Godeau
Nov 26, 2008·Best Practice & Research. Clinical Rheumatology·Bruno Fautrel
Mar 31, 2009·Seminars in Hematology·Douglas B CinesRoberto Stasi
Apr 28, 2009·Blood·Douglas B CinesEline T Luning Prak

❮ Previous
Next ❯

Citations

Nov 28, 2014·Immunologic Research·Carlo PerriconeGuido Valesini
Aug 14, 2013·British Journal of Haematology·Christopher G J McKenzieJohn W Semple
Oct 22, 2010·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Lorenzo CirasinoGiancarlo A Palmieri
Apr 1, 2017·Jornal Vascular Brasileiro·Andreas FunkeRoger Abramino Levy
Nov 18, 2021·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Shasha ZhaoRunhui Wu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

HIV/AIDS-Related Malignancies

HIV/AIDS infection increases the risk of non-communicable diseases common in the aged including HIV/AIDS-related malignancies. Discover the latest research in HIV/AIDS-related malignancies.

B cell Activation

B cell activation is initiated by the ligation of the B cell receptor with antigen and ultimately results in the production of protective antibodies against potentially pathogenic invaders. Here is the latest research.

Related Papers

Hematology/oncology Clinics of North America
Bethan Psaila, James B Bussel
Journal of Pediatric Hematology/oncology
Drew Provan, Adrian Newland
Nihon rinsho. Japanese journal of clinical medicine
Hiroyuki OhtakeMasaaki Higashihara
© 2022 Meta ULC. All rights reserved